{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:34:21Z","timestamp":1787758461729,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>Autologous stem cell transplantation (ASCT) is a well-established consolidation treatment for many hematologic cancers which delivers prolonged survival. A subset of patients\u2019 adequate stem cell harvest is not achievable with a solitary use of granulocyte colony-stimulating agents (G-CSF). Generally, chemomobilization is employed for patients failing G-CSF and its most feared complication febrile neutropenia (FN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>Here, we aimed to investigate the impact of the FN in chemomobilization on apheresis outcomes and engraftment. One hundred and eighty-three patients with the diagnosis of lymphoma or myeloma who underwent chemomobilization between 2015 and 2020 were included in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Forty-three patients experienced FN. All patients received G-CSF. All myeloma patients were mobilized with 4 g\/m\n                      <jats:sup>2<\/jats:sup>\n                      cyclophosphamide, but it was heterogeneous for lymphoma patients. The precollection blood counts, harvested CD34+ hematopoietic stem cells (HSCs)\/kg, apheresis count, and engraftment durations were recorded. Preapheresis leukocyte and platelet were lower in the FN group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0,004 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0,001). Peripheral CD34 HSCs and total harvested CD34 HSCs were similar among groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.25 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.9). More apheresis was needed in the FN group, but it was not significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.07). Undergoing ASCT was similar (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.7); however, platelet and neutrophil engraftment durations were slower in the FN group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.05 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Harvesting sufficient CD34+ HSCs from patients with FN is still feasible; however, FN treatment should begin promptly, and further apheresis sessions may be required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ajts.ajts_152_21","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T04:48:23Z","timestamp":1664254103000},"page":"21-26","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Is neutropenic fever an obstacle to effective stem cell harvesting?"],"prefix":"10.4103","volume":"18","author":[{"given":"Semih","family":"Ba\u015fc\u0131","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersin","family":"Bozan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samet","family":"Yaman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar Uncu","family":"Ulu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Bak\u0131rta\u015f","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011f\u00e7e Nur","family":"Yi\u011feno\u011flu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"K\u0131l\u0131n\u00e7","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurg\u00fcl","family":"\u00d6zcan","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merih K\u0131z\u0131l","family":"\u00c7akar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi","family":"Altunta\u015f","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed hodgkin's lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive hodgkin's disease:A randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/jca.21605","article-title":"Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+cell collection and increased apheresis collection days","volume":"33","author":"Khouri","year":"2018","journal-title":"J Clin Apher"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes:Consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/bmt.2008.410","article-title":"Improving stem cell mobilization strategies:Future directions","volume":"43","author":"Bensinger","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"e2012066","DOI":"10.4084\/mjhid.2012.066","article-title":"New strategies for stem cell mobilization","volume":"4","author":"Lemoli","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","article-title":"A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients","volume":"27","author":"Fitoussi","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bmt.1703307","article-title":"Infections during mobilizing chemotherapy and following autologous stem cell transplantation","volume":"28","author":"Toor","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/152581603321628296","article-title":"Infectious complications in patients receiving mobilization chemotherapy for autologous peripheral blood stem cell collection","volume":"12","author":"Jillella","year":"2003","journal-title":"J Hematother Stem Cell Res"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient management of fever and neutropenia in adults treated for malignancy:American society of clinical oncology and infectious diseases society of America clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1200\/JCO.2014.57.2347","article-title":"Prediction of serious complications in patients with seemingly stable febrile neutropenia:Validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study","volume":"33","author":"Carmona-Bayonas","year":"2015","journal-title":"J Clin Oncol"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/CCM.0b013e31822b50c2","article-title":"Survival in neutropenic patients with severe sepsis or septic shock","volume":"40","author":"Legrand","year":"2012","journal-title":"Crit Care Med"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41375-020-0922-x","article-title":"Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+cells without antithymocyte globulin","volume":"35","author":"Politikos","year":"2021","journal-title":"Leukemia"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.transci.2016.11.005","article-title":"How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?","volume":"56","author":"Ataca Atilla","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/bmt.2010.336","article-title":"Apheresis days required for harvesting CD34+cells predicts hematopoietic recovery and survival following autologous transplantation","volume":"46","author":"Malik","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jca.21556","article-title":"Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"33","author":"Moreb","year":"2018","journal-title":"J Clin Apher"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.transci.2017.11.028","article-title":"Current status of art mobilization in myeloma","volume":"56","author":"Sevindik","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"102722","DOI":"10.1016\/j.transci.2020.102722","article-title":"Inferior prognosis in poor mobilizing myeloma patients","volume":"59","author":"Yi\u011feno\u011flu","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"102595","DOI":"10.1016\/j.transci.2019.06.023","article-title":"Predictive factors for stem cell mobilization failure in multiple myeloma patients:A single center experience","volume":"59","author":"Goker","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.transci.2017.11.024","article-title":"Hematopoietic progenitor cell mobilization","volume":"56","author":"Altunta\u015f","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/bmt.2014.322","article-title":"Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation","volume":"50","author":"Brioli","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jca.21688","article-title":"Neutropenic fever and stem cell mobilization","volume":"34","author":"Topcuoglu","year":"2019","journal-title":"J Clin Apher"}],"container-title":["Asian Journal of Transfusion Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ajts.ajts_152_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:14:56Z","timestamp":1787757296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ajts.ajts_152_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ajts.ajts_152_21","relation":{},"ISSN":["0973-6247","1998-3565"],"issn-type":[{"value":"0973-6247","type":"print"},{"value":"1998-3565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"2021-10-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}